ClinicalTrials.gg
Not yet recruitingNCT07949578Updated Nov 19, 2026

DNA Methylation-Based Testing for High Risk Populations

An interventional study of Galleri Multi-Cancer Early Detection (MCED) in Genetic Predisposition to Cancer and Pancreatic Cystic Neoplasm, sponsored by University of Colorado, Denver. Not yet recruiting at 1 site in United States. Open to participants aged 40 Years and older. Per ClinicalTrials.gov, last updated 2026-11-19.

Sponsored by University of Colorado, Denver · Not applicable, Interventional, and Screening

How we know

Updated Nov 19, 2026Newly registeredGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
176
Allocation
Not applicable
Ages
40 Years and older
Sex
All
01

Study summary

This study will study the feasibility of using multi-cancer early detection (MCED) testing in individuals at high risk for cancer development. We will look at participants to have germline mutations in cancer associated genes and participants who have pancreatic cysts. Participants will undergo testing and complete questionnaires to evaluating anxiety and adherence to standard screening after testing.

Read the detailed description

This study is evaluating the feasibility of using multi-cancer early detection (MCED) testing in individuals at high risk for cancer development. This will be done in two high risk populations. Participants with pathogenic or likely pathogenic germline mutations associated with moderate to high penetrance for cancer development (Cohort A) and those with high-risk pancreatic cysts (Cohort B).

Eligible participants will undergo testing and complete questionnaires to evaluating anxiety and adherence to standard screening after testing.

02

Conditions studied

  • Genetic Predisposition to Cancer
  • Pancreatic Cystic Neoplasm
03

In context

Lead sponsor

University of Colorado, Denver is the lead sponsor of 1,547 studies on the registry; 318 are open to participants now.

Of its 147 completed or terminated interventional studies of FDA-regulated products, 92 (63%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
40 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Provision to sign and date the consent form. Patients will be offered an electronic consent via REDCap, or they may use a paper copy.
  • Stated willingness to comply with all study procedures and be available for the duration of the study.
  • Be an adult aged 40 years or older.
  • Individuals will be eligible to enroll into Cohort A if they are being evaluated within the University of Colorado's Hereditary Cancer Clinic and have a known germline pathogenic or likely pathogenic germline mutation of any of the following genes:
  • BRCA 1, BRCA 2, PALB2, MLH 1, MSH 2, MSH 6, ATM, CHEK2, PTEN, CDH1, TP 53, STK11.
  • Individuals will be eligible to enroll into Cohort B if they are being evaluated within the University of Colorado's Pancreatic Cyst Surveillance Clinic and have 1 or more of the following risk factors for development of pancreatic :
  • Pancreatic cyst greater than or equal to 2.5 cm, greater than or equal to 5 mm increase in size per year, greater than or equal to 10 mm growth since initiation of surveillance, cyst associated with mass or mural nodule, dilated pancreatic duct greater than or equal to 5 mm, new onset diabetes, CA 19-9 greater than or equal to 37 U/mL.
  • Individuals with a history of cancer that was definitively managed 3 or more years prior to enrollment and/or those with a history of cutaneous squamous cell carcinoma or basal cell carcinoma diagnosed at any time will be allowed to participate. Patients on long term therapies, (for example, hormonal therapies for breast cancer) are allowed to participate.

Exclusion criteria

Exclusion Criteria:

  • Individuals less than 40 years old.
  • Individuals with a history of cancer that was treated within 3 years prior to enrollment in the study. Patients on long term therapies, (for example, hormonal therapies for breast cancer) are allowed to participate.
  • Individuals with known active cancer.
  • Individuals currently undergoing diagnostic evaluation for a suspicion of having a cancer diagnosis/recurrence.
  • Individuals who are known to be pregnant.
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Adjuvant and neoadjuvant

Neoadjuvant treatment is given before the main treatment (usually surgery), often to shrink a tumor. Adjuvant treatment is given after it, to lower the chance of the cancer coming back.

05

Study design

Phase
Not applicable
Primary purpose
Screening
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
176 participants (estimated)

Study arms

  • Experimental
    MCED Testing

    Participants in two high-risk cohorts (germline mutation carriers and individuals with high-risk pancreatic cysts) undergo Galleri multi-cancer early detection testing and follow-up assessments.

    Diagnostic Test: Galleri Multi-Cancer Early Detection (MCED)

Interventions

  • Diagnostic testGalleri Multi-Cancer Early Detection (MCED)

    Patients who decide to enroll will undergo a blood draw to complete the Galleri MCED test and banking for future research, along with baseline sociodemographic, anxiety, cancer screening adherence, and cancer history questionnaires. After completing Galleri testing and receiving the results, patients will be directed to the cancer diagnostics clinic at AMC if they have a positive result. All patients will complete repeat anxiety, cancer history, and cancer screening adherence questionnaires at the 1-year and 2-year timepoints.

06

What researchers measure

Primary outcomes

  1. Feasibility of MCED testing in high risk populations

    Feasibility will be established if 50% or more of participants offered MCED testing on this protocol accept, complete consent, and undergo MCED testing and if greater than or equal to 75% of participants with a positive MCED test complete evaluation in the Diagnostic Clinic.

    Time frame: 2 years

Secondary outcomes

  1. Evaluate anxiety associate with MCED testing

    Anxiety will be assessed by the Impact of Events Survey and GAD-7 Survey. Participants who complete the validated anxiety questionnaires at baseline and at least one follow-up time point will be included. Change scores will be analyzed using paired methods within participants and between MCED test result groups. Anxiety scores will be summarized descriptively at each assessment time point using means, standard deviations, medians, and interquartile ranges. Change from baseline will also be summarized descriptively for each time point.

    Time frame: Anxiety will be assessed at Baseline, 1 year after MCED testing, and 2 years after MCED testing

  2. Evaluate adherence to standard screening for individuals undergoing MCED testing

    Participants who complete the validated cancer screening adherence questionnaire at baseline and at least one follow-up time point will be included. Change scores will be analyzed using paired methods within participants and between MCED test result groups. Adherence to standard of care cancer screening testing will be summarized descriptively at each assessment time point using means, standard deviations, medians, and interquartile ranges. Change from baseline will also be summarized descriptively for each time point.

    Time frame: Cancer screening adherence will be assessed at Baseline, 1 year after MCED testing, and 2 years after MCED testing

07

Study locations

1 site
08

References and documents

Individual participant data

Plan to share: Undecided — We need to consider what will and will not be shared given that this is a single institution trial

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Start is estimated for Jan 2027; primary completion for Apr 2030, 39 months later.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 14, 2026
First posted
Nov 19, 2026
StartEst.
Jan 2027
Primary completionEst.
Apr 2030
CompletionEst.
Apr 2031
Last update
Nov 19, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Registered
First appeared on the registry. No changes since
Nov 19, 2026
Show all 1 update
  1. Nov 19, 2026
    First appeared on the registry

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07949578
Collaborators
GRAIL, Inc.
Responsible party
Sponsor
First posted
Nov 19, 2026
Start date
Jan 2027 (estimated)
Primary completion
Apr 2030 (estimated)
Completion
Apr 2031 (estimated)
Last update
Nov 19, 2026

Study contacts

Marie Wood, MD
principal investigator · University of Colorado, Denver

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Nov 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion